A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene
- PMID: 15869924
- DOI: 10.1016/j.bone.2005.02.019
A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene
Abstract
In this study, a brother and sister of German origin are described with a possible diagnosis of van Buchem disease, a rare autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis of the skeleton mainly affecting the cranial bones. Clinically, patients suffer from cranial nerve entrapment potentially resulting in facial paresis, hearing disturbances, and visual loss. The radiological picture of van Buchem disease closely resembles sclerosteosis, although in the latter patients, syndactyly, tall stature, and raised intracranial pressure are frequently observed, allowing a differential diagnosis with van Buchem disease. Previous molecular studies demonstrated homozygous loss-of-function mutations in the SOST gene in sclerosteosis patients while a chromosomal rearrangement creating a 52-kb deletion downstream of this gene was found in Dutch patients with van Buchem disease. This deletion most likely suppresses SOST expression. Sclerostin, the SOST gene product, has been shown to play a role in bone metabolism. The two siblings reported here were evaluated at the molecular level by carrying out a mutation analysis of the SOST gene. This resulted in the identification of a novel putative disease-causing splice site mutation (IVS1 + 1 G-->C) homozygously present in both siblings.
Similar articles
-
Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?J Musculoskelet Neuronal Interact. 2004 Jun;4(2):139-42. J Musculoskelet Neuronal Interact. 2004. PMID: 15615113 Review.
-
First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.Hum Mutat. 2010 Jul;31(7):E1526-43. doi: 10.1002/humu.21274. Hum Mutat. 2010. PMID: 20583295
-
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27. doi: 10.1016/j.cytogfr.2005.02.005. Cytokine Growth Factor Rev. 2005. PMID: 15869900 Review.
-
Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.Metabolism. 2018 Mar;80:38-47. doi: 10.1016/j.metabol.2017.10.005. Epub 2017 Oct 25. Metabolism. 2018. PMID: 29080811 Review.
-
Novel SOST gene mutation in a sclerosteosis patient from Morocco: a case report.Eur J Med Genet. 2014 Mar;57(4):133-7. doi: 10.1016/j.ejmg.2014.02.007. Epub 2014 Mar 1. Eur J Med Genet. 2014. PMID: 24594238
Cited by
-
Identification of osteocyte-selective proteins.Proteomics. 2010 Oct;10(20):3688-98. doi: 10.1002/pmic.201000306. Proteomics. 2010. PMID: 20845334 Free PMC article.
-
Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants.Tissue Eng Part A. 2018 Nov;24(21-22):1672-1679. doi: 10.1089/ten.TEA.2018.0013. Epub 2018 Sep 6. Tissue Eng Part A. 2018. PMID: 29921173 Free PMC article.
-
Sclerostin antibody increases bone volume and enhances implant fixation in a rat model.J Bone Joint Surg Am. 2012 Sep 19;94(18):1670-80. doi: 10.2106/JBJS.K.00344. J Bone Joint Surg Am. 2012. PMID: 22992878 Free PMC article.
-
Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry.J Transl Med. 2022 May 13;20(1):221. doi: 10.1186/s12967-022-03417-4. J Transl Med. 2022. PMID: 35562828 Free PMC article. Review.
-
A review of osteocyte function and the emerging importance of sclerostin.J Bone Joint Surg Am. 2014 Oct 1;96(19):1659-68. doi: 10.2106/JBJS.M.01096. J Bone Joint Surg Am. 2014. PMID: 25274791 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
